Display options
Cite
Stuard S, Cesarone MR, Belcaro G, et al. Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides: safety aspects. Int J Angiol. 2008;17(3):143-8doi: 10.1055/s-0031-1278299.
Stuard, S., Cesarone, M. R., Belcaro, G., Dugall, M., Ledda, A., Cacchio, M., Ricci, A., Ippolito, E., Di Renzo, A., & Grossi, M. G. (2008). Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides: safety aspects. The International journal of angiology : official publication of the International College of Angiology, Inc, 17(3), 143-8. https://doi.org/10.1055/s-0031-1278299
Stuard, S, et al. "Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides: safety aspects." The International journal of angiology : official publication of the International College of Angiology, Inc vol. 17,3 (2008): 143-8. doi: https://doi.org/10.1055/s-0031-1278299
Stuard S, Cesarone MR, Belcaro G, Dugall M, Ledda A, Cacchio M, Ricci A, Ippolito E, Di Renzo A, Grossi MG. Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides: safety aspects. Int J Angiol. 2008;17(3):143-8. doi: 10.1055/s-0031-1278299. PMID: 22477419; PMCID: PMC2727765.
Copy Download .nbib Format: NLM
Share it on

Int J Angiol. 2008;17(3):143-8. doi: 10.1055/s-0031-1278299.

Five-year treatment of chronic venous insufficiency with O-(β-hydroxyethyl)-rutosides: safety aspects.

The International journal of angiology : official publication of the International College of Angiology, Inc

S Stuard, Maria Rosaria Cesarone, Gianni Belcaro, Mark Dugall, Andrea Ledda, Marisa Cacchio, Andrea Ricci, Edmondo Ippolito, Andrea Di Renzo, Maria Giovanna Grossi

Affiliations

  1. Unitá Operative Dialisi/Diaferesi, L'Aquila.

PMID: 22477419 PMCID: PMC2727765 DOI: 10.1055/s-0031-1278299

Abstract

Chronic venous insufficiency (CVI), and related signs and symptoms of venous and diabetic microangiopathy, can be effectively treated with O-(β-hydroxyethyl)-rutosides (HR). The aim of the present independent registry study was to evaluate HR in a long-term (five-year) period of administration that examined the tolerability and safety of HR. Patients with severe CVI and venous microangiopathy were included in the registry. Subjects who completed five years of treatment were considered in the analysis. Blood parameters, liver and renal function tests, microalbuminuria (in diabetic patients) and cholesterol levels were evaluated to assess the effects of HR treatment. Four groups were studied - group A (98 patients) received oral HR (1500 mg per day), group B (87 diabetic patients with CVI) was treated with 2 g of HR per day, group C (90 controls, including 42 diabetic patients) had no pharmacological treatment and group D (113 patients, including 48 diabetic patients) used elastic stockings. No significant negative changes in blood parameters were recorded at two and five years. Decreases in microalbuminuria and total cholesterol, and an increase in high-density lipoprotein cholesterol were observed in HR-treated patients, particularly in diabetic patients. Minimal (nonsignificant) variations were observed in the groups that did not use HR. In conclusion, HR treatment is safe, and some positive effects from HR on cholesterol levels and microalbuminuria (in diabetic patients) that were previously observed may suggest potential new clinical applications.

References

  1. Int J Microcirc Clin Exp. 1982;1(1):5-17 - PubMed
  2. Colloids Surf B Biointerfaces. 2006 Sep 1;52(1):8-13 - PubMed
  3. Cardiovasc Drugs Ther. 1998 Sep;12(4):375-81 - PubMed
  4. Vasa. 1982;11(2):101-3 - PubMed
  5. Vasa. 1994;23(3):244-50 - PubMed
  6. J Cardiovasc Pharmacol Ther. 2002 Jan;7 Suppl 1:S3-6 - PubMed
  7. Rapid Commun Mass Spectrom. 2006;20(23):3522-6 - PubMed
  8. Biofactors. 2005;24(1-4):291-8 - PubMed
  9. J Cardiovasc Pharmacol Ther. 2002 Jan;7 Suppl 1:S17-20 - PubMed
  10. Arzneimittelforschung. 2005;55(10):573-80 - PubMed
  11. Angiology. 1992 Jun;43(6):490-5 - PubMed
  12. Phytomedicine. 2005 Jan;12(1-2):52-61 - PubMed
  13. Int J Gynaecol Obstet. 2007 Jul;98(1):29-33 - PubMed
  14. Angiology. 2001 Aug;52 Suppl 1:S43-7 - PubMed
  15. Acta Physiol Scand. 1976 Aug;97(4):447-56 - PubMed
  16. Circulation. 1984 Nov;70(5):806-11 - PubMed
  17. Am J Epidemiol. 2003 Oct 1;158(7):676-86 - PubMed
  18. Vasa. 1989;18(2):146-51 - PubMed
  19. Vasa. 1989;18(2):136-9 - PubMed
  20. Phlebologie. 1988 Nov-Dec;41(4):847-56 - PubMed
  21. G Ital Nefrol. 2002 May-Jun;19(3):273-7 - PubMed
  22. Angiology. 2006 Mar-Apr;57(2):131-8 - PubMed
  23. Lancet. 1952 Oct 25;2(6739):789-94 - PubMed
  24. J Cardiovasc Pharmacol Ther. 2002 Jan;7 Suppl 1:S25-8 - PubMed
  25. J Cardiovasc Pharmacol Ther. 2002 Jan;7 Suppl 1:S7-S10 - PubMed
  26. J Cardiovasc Pharmacol Ther. 2002 Jan;7 Suppl 1:S21-4 - PubMed
  27. Mol Cell Biochem. 2005 Dec;280(1-2):57-68 - PubMed
  28. Ann Vasc Surg. 1989 Jan;3(1):5-7 - PubMed
  29. J Nutr. 2004 Aug;134(8):1874-80 - PubMed
  30. Vasa. 1992;21(1):76-80 - PubMed
  31. Br Med J (Clin Res Ed). 1986 Jan 11;292(6513):87-90 - PubMed
  32. Int J Food Sci Nutr. 2007 Mar;58(2):87-93 - PubMed
  33. Phytother Res. 2006 Jul;20(7):542-5 - PubMed
  34. Mol Nutr Food Res. 2007 Aug;51(8):956-61 - PubMed
  35. Angiology. 2005 Mar-Apr;56(2):165-72 - PubMed
  36. J Inorg Biochem. 2007 Jun;101(6):935-43 - PubMed
  37. Angiology. 2008 Feb-Mar;59 Suppl 1:7S-13S - PubMed
  38. J Cardiovasc Pharmacol Ther. 2002 Jan;7 Suppl 1:S11-5 - PubMed
  39. Angiology. 2008 Feb-Mar;59 Suppl 1:14S-20S - PubMed
  40. J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):93-8 - PubMed
  41. Angiology. 2005 May-Jun;56(3):289-93 - PubMed

Publication Types